Atuka provides contract research and consultancy services for the biopharmaceutical industry with world-leading expertise in Parkinson’s disease and related neurological conditions. We provide cutting-edge, rodent and non-human primate models (toxin and molecular pathology-driven) to evaluate efficacy and target engagement over a comprehensive range of symptomatic, motor (e.g. parkinsonism and dyskinesia), non-motor (e.g. cognition and impulse control) and disease-modification assays. Atuka also offers medicinal chemistry, DMPK and in-vivo imaging services to aid development of novel therapeutics.
The Jackson Laboratory (JAX) is an independent, nonprofit biomedical research institute combining innovation, reliability, and commitment to customer service to provide the most clinically relevant mouse models and precision services. With an extensive and ever expanding portfolio of mouse models and services such as target validation and drug efficacy studies, JAX is committed to providing researchers with the most advanced tools
to support their neurobiological research and enable efficacious drug design.
Certara is the global leader in advancing modern, efficient drug development. We provide proven modeling & simulation, regulatory and real world value assessment software and services. In partnership with our clients, we help reduce clinical trial burden, accelerate regulatory approval and increase patient access to medicines. 90% of all novel drugs approved by FDA have used Certara software and/or services.
Proprietary MultiBrain® technology powers NSA’s simultaneous sectioning, and expertly-guided staining, of up to 40 neuronal tissues in one MultiBrain® block, achieving uniform processing across all 40 tissues. Implementing NSA’s Large Format™ technology enables sectioning and staining of intact human brain hemispheres and yields comprehensive, uninterrupted vantage and analysis of the ultimate target. Coupling these mass production technologies with cutting-edge digital image capture and hosting, along with contemporary analysis tools increasingly powered by AI, rapidly produces rich data, and dramatically reduces R&D times.
Aiforia using AI to push the boundaries of Image Analysis, cloud-based platform that increases the speed, accuracy and consistency of analyzing large and complex medical images across a variety of fields (such as NDD). The precise and robust technology, based on deep-learning AI, is intuitive and only requires an internet connection and the user’s own domain knowledge to begin training AI models, which can help solve some of today’s most complex image analysis problems facing researchers, pathologists, neuroscientist.
Axol, the hiPSC-Derived cell culture specialists, produce high quality human cell products for the range of neuroscience research needs. Our expertise includes reprogramming cells to iPSCs and then differentiating to various cell types, supplying differentiated cells derived from healthy donors and patients of specific disease backgrounds, such as Alzheimer's, Huntington's and Parkinson's. We also take cells provided by customers (primary or iPSC), reprogram when necessary and differentiate to order. Axol holds the necessary licenses required to do iPSC work.
BrainWaveBank offer a unique wearable EEG device to objectively and conveniently measure the mechanisms that underpin neurological disorders and therapies. Gamified tasks engage users to assess cognitive domains repeatedly, allowing us to longitudinally sample both brain activity and relevant domains - all seamlessly, from distributed trial centres through to unsupervised use in the patient’s home. With our cloud-based machine learning algorithms we develop digital markers to support patient stratification and measurement of treatment response.
Ulysses Neuroscience Ltd. is a Private R&D Organization having a more collaborative way of working with pharmaceutical companies. Our research investigates the molecular mechanisms leading to the synaptic pathology which may anticipate development of neurodegenerative disorders. We adopt a translational approach identifying synaptic and cytoskeletal targets in diseased populations that can then be explored in animal models. “Aged rodents” is the naturalistic model of MCI/AD used to investigate pro-cognitive and molecular efficacy of novel compounds.
Olink provides a protein biomarker discovery service that delivers unparalleled data quality in a high-multiplex. Specifically, from 1ul of plasma or CSF we will deliver 92 highly validated protein measurements, and from 15ul we can deliver 1161 validated datapoints. We enable precision medicine initiatives for clients looking for disease prognostic, pharmacodynamic, or response-signature biomarkers.
QPS is a global CRO providing discovery, preclinical and clinical drug development services since 1995. Our mission is to accelerate pharmaceutical breakthroughs across the globe by delivering custom-built research services. QPS is known for proven quality standards, technical expertise, a flexible approach to research, high client satisfaction and turnkey laboratories and facilities. Our profound expertise in neuroscience and two decades of experience in contract research results in a sustainable advantage for our customers.
Rho, a contract research organization (CRO) located in Durham, NC, provides a full range of services across the entire drug development process. For more than 30 years, Rho has been a trusted partner to leading pharmaceutical, biotechnology, and medical device companies as well as academic and government organizations. Our commitment to excellence, innovative technologies, and therapeutic expertise accelerate time to market, maximize returns on investment, and lead to an exceptional customer experience.
Invitae’s mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Our goal is to aggregate most of the world’s genetic tests into a single service with higher quality, faster turnaround time and lower prices.
Established in 2007, Quanterix is a company that is digitizing biomarker analysis with the goal of advancing the science of precision health. Our technology platform, Simoa®, has the potential to change today’s approach to healthcare by giving researchers the ability to closely examine the continuum from health to disease. Simoa® is designed to enable earlier disease detection, better prognoses and enhanced treatment methods. The company is located in Billerica, MA.
Gubra is a privately-held Danish biotech and contract research company delivering scientific counselling and preclinical services within metabolic diseases. Gubra experts cover various pre-clinical disciplines including in vivo pharmacology and histology – with a specific expertise in the application of stereology and 3D imaging. Co-founder, Jacob Jelsing, has led several preclinical studies in neurodegenerative diseases and will be presenting novel 3D imaging methods for assessment of whole brain structural changes in Parkinson and Alzheimer´s Disease.
B'SYS GmbH is a leading European Ion Channel CRO and has a comprehensive library of validated human ion channel expressing cell lines. With its team of experienced electrophysiologists and state-of-the-art facilities in Switzerland, B’SYS serves the needs of pharmaceutical and biotech customers worldwide since 2003.
B’SYS works closely with its customers to speed the drug-development process and therefore to save time and money on the way to better and safer drugs. B’SYS services include:
Automated patch-clamping on 3 automated patch clamp setups
Manual patch-clamp recordings on 9 manual patch-clamp rigs, 5 of which equipped with rapid solution management/gating for ligand-gated ion channels with minimal compound consumption.
Fluorescence and Luminescence screening™
Proprietary ion channel cell lines (CNS and cardiac safety relevant), validated for manual as well as automated patch-clamp recordings
• action potential studies on iPS-derived cardiomyocytes